ZYME 内幕交易
ZYME 的 SEC Form 4 内幕交易记录
总交易
56
买入
0
买入总额
-
卖出总额
$11.6M
| 信号 | 内幕人 | 职位 | 方向 | 股数 | 价格 | 金额 | 日期 | 信号原因 |
|---|---|---|---|---|---|---|---|---|
| ★★★★★(33) | SMITH JEFFREY T L | EVP & Chief Medical Officer | 卖出 | 247,333 | $24.80 | $6.1M | 2026-03-06 | 高管卖出, 超大额卖出(>$5M) |
| ★★★★★(33) | GALBRAITH KENNETH | - | 卖出 | 30,424 | $23.17 | $705K | 2026-01-12 | 高管卖出, 董事卖出 |
| ★★★★★(26) | SMITH JEFFREY T L | EVP & Chief Medical Officer | 卖出 | 9,310 | $22.67 | $211K | 2026-01-12 | 高管卖出, 非10b5-1计划卖出 |
| ★★★★★(25) | HOLLYWOOD MARK | EVP & Chief Operating Officer | 卖出 | 6,120 | $22.67 | $139K | 2026-01-12 | C-suite卖出, 非10b5-1计划卖出 |
| ★★★★★(20) | PATTERSON LEONE D | - | 卖出 | 128,548 | $23.17 | $3.0M | 2026-02-13 | 百万级卖出, 非10b5-1计划卖出 |
| ★★★★★(18) | SCHAYOWITZ ADAM | Exhibit List - Exhibit 24 - Power of Attorney EVP, Head of Research & Development | 卖出 | 13,832 | $25.26 | $349K | 2026-10-09 | 高管卖出, 非10b5-1计划卖出 |
| ★★★★★(18) | MOORE PAUL ANDREW | - | 卖出 | 9,560 | $23.17 | $222K | 2026-01-12 | 高管卖出, 非10b5-1计划卖出 |
| ★★★★★(15) | PATTERSON LEONE D | - | 卖出 | 31,641 | $22.60 | $715K | 2026-02-17 | 大额卖出(>$500K), 非10b5-1计划卖出 |
| ★★★★★(10) | PATTERSON LEONE D | - | 卖出 | 6,832 | $23.17 | $158K | 2026-01-12 | 非10b5-1计划卖出 |
| ★★★★★(0) | SCHAYOWITZ ADAM | EVP, Head of R&D | 卖出 | 37,037 | - | - | 2026-10-09 | |
| ★★★★★(0) | HOLLYWOOD MARK | EVP & Chief Operating Officer | 卖出 | 939 | $22.22 | $21K | 2026-07-06 | |
| ★★★★★(0) | SCHNEIDER PAUL R | EVP, General Counsel | 卖出 | 119,000 | - | - | 2026-05-13 | |
| ★★★★★(0) | SCHNEIDER PAUL R | EVP, General Counsel | 卖出 | 178,000 | - | - | 2026-05-13 | |
| ★★★★★(0) | SCHNEIDER PAUL R | EVP, General Counsel | 卖出 | 0 | - | - | 2026-05-13 | |
| ★★★★★(0) | SCHAYOWITZ ADAM | EVP, Head of Research & Development | 卖出 | 47,000 | - | - | 2026-04-09 | |
| ★★★★★(0) | PLATSHON SCOTT | EVP, Chief Business Officer | 卖出 | 0 | - | - | 2026-04-09 | |
| ★★★★★(0) | SCHAYOWITZ ADAM | EVP, Head of Research & Development | 卖出 | 76,000 | - | - | 2026-04-09 | |
| ★★★★★(0) | PLATSHON SCOTT | EVP, Chief Business Officer | 卖出 | 70,000 | - | - | 2026-04-09 | |
| ★★★★★(0) | PLATSHON SCOTT | EVP, Chief Business Officer | 卖出 | 76,000 | - | - | 2026-04-09 | |
| ★★★★★(0) | SCHAYOWITZ ADAM | EVP, Head of Research & Development | 卖出 | 70,000 | - | - | 2026-04-09 | |
| ★★★★★(0) | PLATSHON SCOTT | EVP, Chief Business Officer | 卖出 | 47,000 | - | - | 2026-04-09 | |
| ★★★★★(0) | SCHAYOWITZ ADAM | Exhibit List - Exhibit 24 - Power of Attorney EVP, Head of Research & Development | 卖出 | 0 | - | - | 2026-04-09 | |
| ★★★★★(0) | STAFFORD KRISTIN | EVP, Chief Financial Officer | 卖出 | 50,000 | - | - | 2026-04-06 | |
| ★★★★★(0) | STAFFORD KRISTIN | EVP, Chief Financial Officer | 卖出 | 119,000 | - | - | 2026-04-06 | |
| ★★★★★(0) | STAFFORD KRISTIN | EVP, Chief Financial Officer | 卖出 | 178,000 | - | - | 2026-04-06 | |
| ★★★★★(0) | STAFFORD KRISTIN | EVP, Chief Financial Officer | 卖出 | 0 | - | - | 2026-04-01 | |
| ★★★★★(0) | MEKAN SABEEN | SVP & Chief Medical Officer | 卖出 | 0 | - | - | 2026-02-01 | |
| ★★★★★(0) | HOLLYWOOD MARK | EVP & Chief Operating Officer | 卖出 | 66,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | HOLLYWOOD MARK | EVP & Chief Operating Officer | 卖出 | 17,666 | - | - | 2026-01-12 | |
| ★★★★★(0) | CHERRY BRIAN N | - | 卖出 | 0 | - | - | 2026-01-12 | |
| ★★★★★(0) | CHERRY BRIAN N | - | 卖出 | 15,400 | - | - | 2026-01-12 | |
| ★★★★★(0) | HOLLYWOOD MARK | EVP & Chief Operating Officer | 卖出 | 47,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | CHERRY BRIAN N | - | 卖出 | 23,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | HOLLYWOOD MARK | EVP & Chief Operating Officer | 卖出 | 70,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | HOLLYWOOD MARK | EVP & Chief Operating Officer | 卖出 | 0 | - | - | 2026-01-09 | |
| ★★★★★(0) | LANDRY ROBERT E | - | 卖出 | 11,500 | - | - | 2026-01-12 | |
| ★★★★★(0) | MOORE PAUL ANDREW | Chief Scientific Officer | 卖出 | 70,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | CAMPOY CARLOS | - | 卖出 | 7,700 | - | - | 2026-01-12 | |
| ★★★★★(0) | GALBRAITH KENNETH | Chair & CEO | 卖出 | 144,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | GALBRAITH KENNETH | Chair & CEO | 卖出 | 216,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | MOORE PAUL ANDREW | Chief Scientific Officer | 卖出 | 47,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | NEU KELVIN | - | 卖出 | 7,700 | - | - | 2026-01-12 | |
| ★★★★★(0) | SMITH JEFFREY T L | EVP & Chief Medical Officer | 卖出 | 17,666 | - | - | 2026-01-12 | |
| ★★★★★(0) | CIONGOLI GREGORY AUSTIN | - | 卖出 | 11,500 | - | - | 2026-01-12 | |
| ★★★★★(0) | MAHONY SUSAN | - | 卖出 | 7,700 | - | - | 2026-01-12 | |
| ★★★★★(0) | MOORE PAUL ANDREW | Chief Scientific Officer | 卖出 | 66,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | GALBRAITH KENNETH | Chair & CEO | 卖出 | 222,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | GALBRAITH KENNETH | Chair & CEO | 卖出 | 64,000 | - | - | 2026-01-12 | |
| ★★★★★(0) | CIONGOLI GREGORY AUSTIN | - | 卖出 | 7,700 | - | - | 2026-01-12 | |
| ★★★★★(0) | CAMPOY CARLOS | - | 卖出 | 11,500 | - | - | 2026-01-12 | |
| ★★★★★(0) | MOORE PAUL ANDREW | Chief Scientific Officer | 卖出 | 17,666 | - | - | 2026-01-12 | |
| ★★★★★(0) | CESANO ALESSANDRA | - | 卖出 | 7,700 | - | - | 2026-01-12 | |
| ★★★★★(0) | NEU KELVIN | - | 卖出 | 11,500 | - | - | 2026-01-12 | |
| ★★★★★(0) | CESANO ALESSANDRA | - | 卖出 | 11,500 | - | - | 2026-01-12 | |
| ★★★★★(0) | MAHONY SUSAN | - | 卖出 | 11,500 | - | - | 2026-01-12 | |
| ★★★★★(0) | LANDRY ROBERT E | - | 卖出 | 7,700 | - | - | 2026-01-12 |